These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 24155041

  • 1. Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies.
    Mellini P, Carafa V, Di Rienzo B, Rotili D, De Vita D, Cirilli R, Gallinella B, Provvisiero DP, Di Maro S, Novellino E, Altucci L, Mai A.
    ChemMedChem; 2012 Nov; 7(11):1905-8. PubMed ID: 24155041
    [Abstract] [Full Text] [Related]

  • 2. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
    Galli U, Mesenzani O, Coppo C, Sorba G, Canonico PL, Tron GC, Genazzani AA.
    Eur J Med Chem; 2012 Sep; 55():58-66. PubMed ID: 22835719
    [Abstract] [Full Text] [Related]

  • 3. The Fungal Metabolite Eurochevalierine, a Sequiterpene Alkaloid, Displays Anti-Cancer Properties through Selective Sirtuin 1/2 Inhibition.
    Schnekenburger M, Mathieu V, Lefranc F, Jang JY, Masi M, Kijjoa A, Evidente A, Kim HJ, Kiss R, Dicato M, Han BW, Diederich M.
    Molecules; 2018 Feb 05; 23(2):. PubMed ID: 29401749
    [Abstract] [Full Text] [Related]

  • 4. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins.
    Botta G, De Santis LP, Saladino R.
    Curr Med Chem; 2012 Feb 05; 19(34):5871-84. PubMed ID: 22998567
    [Abstract] [Full Text] [Related]

  • 5. Recent advances in inhibitors of sirtuin1/2: an update and perspective.
    Zhou Z, Ma T, Zhu Q, Xu Y, Zha X.
    Future Med Chem; 2018 Apr 01; 10(8):907-934. PubMed ID: 29642711
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines.
    Ceballos MP, Decándido G, Quiroga AD, Comanzo CG, Livore VI, Lorenzetti F, Lambertucci F, Chazarreta-Cifre L, Banchio C, Alvarez ML, Mottino AD, Carrillo MC.
    Toxicol Lett; 2018 Jun 01; 289():63-74. PubMed ID: 29545174
    [Abstract] [Full Text] [Related]

  • 7. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.
    Huhtiniemi T, Suuronen T, Lahtela-Kakkonen M, Bruijn T, Jääskeläinen S, Poso A, Salminen A, Leppänen J, Jarho E.
    Bioorg Med Chem; 2010 Aug 01; 18(15):5616-25. PubMed ID: 20630764
    [Abstract] [Full Text] [Related]

  • 8. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects.
    Choi G, Lee J, Ji JY, Woo J, Kang NS, Cho SY, Kim HR, Ha JD, Han SY.
    Int J Oncol; 2013 Oct 01; 43(4):1205-11. PubMed ID: 23900402
    [Abstract] [Full Text] [Related]

  • 9. Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology.
    Robers MB, Loh C, Carlson CB, Yang H, Frey EA, Hermanson SB, Bi K.
    Mol Biosyst; 2011 Jan 01; 7(1):59-66. PubMed ID: 20931131
    [Abstract] [Full Text] [Related]

  • 10. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer.
    Hoffmann G, Breitenbücher F, Schuler M, Ehrenhofer-Murray AE.
    J Biol Chem; 2014 Feb 21; 289(8):5208-16. PubMed ID: 24379401
    [Abstract] [Full Text] [Related]

  • 11. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.
    Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, Martinez-Chantar ML, Varela-Rey M, Rotili D, Nebbioso A, Ropero S, Montoya G, Oyarzabal J, Velasco S, Serrano M, Witt M, Villar-Garea A, Imhof A, Mato JM, Esteller M, Fraga MF.
    Oncogene; 2009 Feb 12; 28(6):781-91. PubMed ID: 19060927
    [Abstract] [Full Text] [Related]

  • 12. Tenovin-6-mediated inhibition of SIRT1/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem/progenitor cells.
    Jin Y, Cao Q, Chen C, Du X, Jin B, Pan J.
    BMC Cancer; 2015 Apr 07; 15():226. PubMed ID: 25884180
    [Abstract] [Full Text] [Related]

  • 13. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2.
    Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EW.
    Mol Cancer Ther; 2010 Apr 07; 9(4):844-55. PubMed ID: 20371709
    [Abstract] [Full Text] [Related]

  • 14. Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile.
    Rotili D, Carafa V, Tarantino D, Botta G, Nebbioso A, Altucci L, Mai A.
    Bioorg Med Chem; 2011 Jun 15; 19(12):3659-68. PubMed ID: 21306905
    [Abstract] [Full Text] [Related]

  • 15. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
    Yang L, Ma X, Yuan C, He Y, Li L, Fang S, Xia W, He T, Qian S, Xu Z, Li G, Wang Z.
    Eur J Med Chem; 2017 Jul 07; 134():230-241. PubMed ID: 28415012
    [Abstract] [Full Text] [Related]

  • 16. Finding Potent Sirt Inhibitor in Coffee: Isolation, Confirmation and Synthesis of Javamide-II (N-Caffeoyltryptophan) as Sirt1/2 Inhibitor.
    Park JB.
    PLoS One; 2016 Jul 07; 11(3):e0150392. PubMed ID: 26986569
    [Abstract] [Full Text] [Related]

  • 17. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
    Yagci S, Gozelle M, Kaya SG, Ozkan Y, Aksel AB, Bakar-Ates F, Dundar Y, Eren G.
    Bioorg Med Chem; 2021 Jan 15; 30():115961. PubMed ID: 33360574
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.
    Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA, Bedalov A.
    Cancer Res; 2006 Apr 15; 66(8):4368-77. PubMed ID: 16618762
    [Abstract] [Full Text] [Related]

  • 19. Sirtuin 1 (SIRT1): the misunderstood HDAC.
    Stünkel W, Campbell RM.
    J Biomol Screen; 2011 Dec 15; 16(10):1153-69. PubMed ID: 22086720
    [Abstract] [Full Text] [Related]

  • 20. Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer.
    Carafa V, Poziello A, Della Torre L, Giovannelli P, Di Donato M, Safadeh E, Yu Z, Baldi A, Castoria G, Tomaselli D, Mai A, Rotili D, Nebbioso A, Altucci L.
    Int J Mol Sci; 2019 Nov 12; 20(22):. PubMed ID: 31726691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.